

(19)



(11)

**EP 1 299 536 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**27.03.2013 Bulletin 2013/13**

(21) Application number: **01947420.4**

(22) Date of filing: **28.06.2001**

(51) Int Cl.:  
**C12N 15/12** <sup>(2006.01)</sup>      **C12N 15/63** <sup>(2006.01)</sup>  
**C07K 14/47** <sup>(2006.01)</sup>      **C07K 16/18** <sup>(2006.01)</sup>  
**A61K 38/17** <sup>(2006.01)</sup>      **A61K 39/395** <sup>(2006.01)</sup>  
**A61K 48/00** <sup>(2006.01)</sup>      **G01N 33/53** <sup>(2006.01)</sup>  
**C12Q 1/68** <sup>(2006.01)</sup>      **A61P 9/00** <sup>(2006.01)</sup>  
**A61P 15/08** <sup>(2006.01)</sup>      **A61P 35/00** <sup>(2006.01)</sup>

(86) International application number:  
**PCT/EP2001/007392**

(87) International publication number:  
**WO 2002/004636 (17.01.2002 Gazette 2002/03)**

(54) **ANTIBODY AND USES RELATING TO ALPHA-T CATENIN**

ANTIKÖRPER UND VERWENDUNG BEZÜGLICH DES ALPHA-T CATENINS

ANTICORPS ET UTILISATIONS RELATIFS À LA CATÉNINE ALPHA-T

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR**

(30) Priority: **12.07.2000 EP 00202472**  
**14.07.2000 US 218309 P**

(43) Date of publication of application:  
**09.04.2003 Bulletin 2003/15**

(73) Proprietor: **Vlaams Interuniversitair Instituut voor Biotechnologie vzw.**  
**9052 Zwijnaarde (BE)**

(72) Inventors:  
 • **VAN ROY, Frans**  
**B-9070 Destelbergen (BE)**  
 • **GOOSSENS, Steven**  
**B-9000 Gent (BE)**  
 • **JANSSENS, Barbara**  
**B-9000 Gent (BE)**  
 • **VANPOUCKE, Griet**  
**B-9820 Merelbeke (BE)**

(56) References cited:  
**WO-A-96/02002 WO-A-98/45319**  
**US-A- 5 470 966**

- **DATABASE SWISSPROT E.B.I., Hinxton U.K.;**  
**Accession Number: Q9UI47, 1 May 2000**  
**(2000-05-01) STAES K ET AL: "ALPHA-CATENIN-LIKE PROTEIN VR22" XP002162169 -& DATABASE EM\_HUM E.B.I., Hinxton, U.K.;**  
**Accession Number: AF091606, 2 January 2000**  
**(2000-01-02) STAES K ET AL: "Homo sapiens alpha-catenin-like protein VR22 mRNA, complete cds." XP002162170 cited in the application**
- **DATABASE EM\_EST EBI Hinxton U.K.;**  
**Accession Number: AW551591, 13 March 2000**  
**(2000-03-13) TANAKA T ET AL: "Mouse Newborn Ovary cDNA Library Mus musculus cDNA clone L0201H02 3', mRNA sequence" XP002183100**
- **DATABASE EM\_EST EBI Hinxton U.K.;**  
**Accession Number: AV279527, 1 November 1999**  
**(1999-11-01) ARAKAWA T ET AL: "Mus musculus adult male testis cDNA, RIKEN full-length enriched library, clone:4933408A16, 3' end partial sequence." XP002183101**
- **DATABASE EM-EST E.B.I., Hinxton, U.K.;**  
**Accession Number: AA400832, 29 April 1997**  
**(1997-04-29) HILLIER L ET AL: "Homo sapiens cDNA clone IMAGE:728263 3' similar to SW: CTNN\_CHICK P30997 ALPHA N-CATENIN ;, mRNA sequence" XP002162171 cited in the application**
- **DATABASE EM\_EST E.B.I., Hinxton, U.K.;**  
**Accession Number: AW444927, 20 February 2000**  
**(2000-02-20) NCI-CGAP: "Homo sapiens cDNA clone IMAGE:2733477 3', mRNA sequence" XP002162172 cited in the application**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 299 536 B1**